(Jerusalem Post) Maayan Jaffe-Hoffman - Six critically ill coronavirus patients in Israel who were treated with Pluristem's placenta-based cell-therapy have survived in a compassionate use trial. Four showed improvement in respiratory parameters and three are in the advanced stages of weaning from ventilators. Pluristem's PLX cells have "immunomodulatory properties," meaning they induce the immune system's natural regulatory cells to reduce inflammation of lung tissue.
2020-04-10 00:00:00Full ArticleBACK Visit the Daily Alert Archive